Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972869 | 0.89 | GAA (0.45) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL29028549 | 0.89 | GAA (0.45) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL11659527 | 0.85 | HPGD (0.44) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL4361572 | 0.84 | OGG1 (0.40) | HPGDKMT2AMEN1HSD17B10ALDH1A1 | |
| SCHEMBL2719604 | 0.81 | KMT2A (0.60) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL8778112 | 0.81 | HPGD (0.54) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL1613109 | 0.81 | HPGD (0.56) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| Hydrochloric Acid SCHEMBL5762590 | 0.79 | HPGD (0.54) | HPGDKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL9722676 | 0.79 | OGG1 (0.42) | HPGDHSD17B10POLBALDH1A1CYP3A4 | |
| SCHEMBL2717154 | 0.79 | MAPT (0.62) | HPGDKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161616-A1 | Method for treating glaucoma IIB | SYNVISTA THERAPEUTICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1785134-A2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1359910-A4 | METHOD FOR TREATING GLAUCOMA II B | ALTEON INC (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1353676-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS | ALTEON INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7026342-B2 | Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds | ALTEON, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-6960605-B2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1359910-A1 | METHOD FOR TREATING GLAUCOMA II B | Alteon, Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1353676-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS | Alteon, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6596744-B2 | Administering thiazole compound for therapy of fibrotic diseases | ALTEON, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020183317-A1 | Method for treating fibrotic diseases or other indications IIC | SYNVISTA THERAPEUTICS, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1248615-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020119970-A1 | Method for treating glaucoma IIB | SYNVISTA THERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002053156-A1 | METHOD FOR TREATING GLAUCOMA II B | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002053161-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001052847-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161616-A1 | Method for treating glaucoma IIB | NDUFB9, NDUFB2, NDUFB7 | HPGD 122/4885KMT2A 4344/4885MEN1 4560/4885 |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | HPGD 604/4885KMT2A 3980/4885MEN1 2110/4885 |
| US-20020183317-A1 | Method for treating fibrotic diseases or other indications IIC | MMP1, COL1A1, COL2A1 | HPGD 113/4885KMT2A 4383/4885MEN1 3696/4885 |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, HSPE1, TXN2 | HPGD 625/4885KMT2A 3877/4885MEN1 3229/4885 |
| US-20020119970-A1 | Method for treating glaucoma IIB | NDUFB9, NDUFB2, NDUFB7 | HPGD 106/4885KMT2A 4252/4885MEN1 4145/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | HPGD 118/4885KMT2A 2545/4885MEN1 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.